Early Detection of Ovarian Cancer by Molecular Targeted Ultrasound Imaging Together with Serum Markers of Tumor-Associated Nuclear Change and Angiogenesis
Abstract
Overall goal of this study was to examine the feasibility of vascular endothelial growth factor receptor -2 (VEGFR-2)- targeted ultrasound molecular imaging for the detection of spontaneous ovarian cancer (OVCA) at early stage in association with serum anti-nuclear matrix protein (anti-NMP) antibodies (a marker of ovarian malignant transformation) and serum IL-16 levels (a marker of ovarian tumor-associated neoangiogenesis, TAN). This goal was realized by two specific aims. The results of this study showed that VEGFR-2-targeted ultrasound molecular imaging agent bound with its target expressed by ovarian tumors and enhanced the signal intensity of ultrasound imaging. This study also showed that serum prevalence of anti-NMP antibodies and levels of IL-16 increased in association with ovarian malignant transformation and OVCA development. Furthermore, tumor-associated serum IL-16 levels were elevated even before the formation of a solid tumor mass in the ovary. VEGFR-2-targeted molecular ultrasound imaging together with serum anti-NMP antibodies and IL-16 levels, improved early detection of OVCA and detected ovarian tumors when it is limited to a part of the ovary. Thus VEGFR-2-targeted imaging agents showed potential to be a feasible imaging agent for early OVCA detection. Additionally, laying hens offer a feasible preclinical model to develop OVCA-preventive antiangiogenic therapeutics targeting VEGFR-2 expressed by tumor associated microvessels.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2014
- Accession Number
- ADA599998
Entities
People
- Animesh Barua
Organizations
- Rush University